Revenue of approximately $890 million, up 49% year-over-year in Q3 2026
Subscribers grew to nearly 2.8 million, up 13% year-over-year in Q3 2026
Tightens full year 2026 revenue guidance to a range of $3.13 billion
World-renowned neuroscientist and tenured Stanford professor brings valuable expertise to the company on making the latest health innovations accessible and actionable
Hims & Hers Health, Inc. (("Hims &,
VANCOUVER, BC, Nov. 9, 2026 /CNW/ -- Stock Preachers News Commentary - Wall Street opens a new week nursing bruises from a rough stretch that sent every major index lower, with the Nasdaq Composite off 3.37% and the
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform
Eli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) today announced an
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The federal government's October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action
The program now includes 14 partners, with new savings on health insights, at-home strength training, daily nutrition, and air medical transport
Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and
New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE:HIMS) between August 4, 2025 and
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the
Affected HIMS Investor Summary Who: Hims & Hers Health, Inc. (NYSE:HIMS)What: Securities fraud class action lawsuit filedClass Period: August 4, 2025 through July 29, 2026Deadline to Seek Lead Plaintiff Status:
NEW YORK, Oct. 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE:HIMS) between August 4, 2025 and July 29,
Washington, D.C.--(Newsfile Corp. - October 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE:HIMS) between August 4, 2025 and
If you purchased or acquired Hims securities between August 4, 2025 and July 29, 2026, and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email
New York, New York--(Newsfile Corp. - October 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE:HIMS) between August 4, 2025 and
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 2, 2026 to file lead plaintiff applications in a
